Rallybio Corporation
RLYB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $636 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $636 | $0 | $0 | $0 |
| % Margin | 100% | – | – | – |
| R&D Expenses | $41,507 | $53,544 | $40,689 | $26,909 |
| G&A Expenses | $19,625 | $25,388 | $27,195 | $18,739 |
| SG&A Expenses | $19,625 | $25,388 | $27,195 | $18,739 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $61,132 | $78,932 | $67,884 | $45,648 |
| Operating Income | -$60,496 | -$78,932 | -$67,884 | -$45,648 |
| % Margin | -9,511.9% | – | – | – |
| Other Income/Exp. Net | $2,721 | $4,368 | $155 | -$1,365 |
| Pre-Tax Income | -$57,775 | -$74,564 | -$67,729 | -$47,013 |
| Tax Expense | $0 | $0 | -$1,075 | $0 |
| Net Income | -$57,775 | -$74,564 | -$66,654 | -$47,013 |
| % Margin | -9,084.1% | – | – | – |
| EPS | -1.33 | -1.84 | -2.09 | -1.46 |
| % Growth | 27.7% | 12% | -43.2% | – |
| EPS Diluted | -1.33 | -1.84 | -2.09 | -1.46 |
| Weighted Avg Shares Out | 43,545 | 40,447 | 31,821 | 32,130 |
| Weighted Avg Shares Out Dil | 43,545 | 40,447 | 31,821 | 32,130 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4,216 | $6,147 | $1,963 | $54 |
| Interest Expense | $0 | $0 | $0 | $10 |
| Depreciation & Amortization | $131 | $150 | $167 | $109 |
| EBITDA | -$60,365 | -$78,782 | -$67,717 | -$45,389 |
| % Margin | -9,491.4% | – | – | – |